OBJECTIVES: ‘Daytime functioning’ is a widely used outcome to describe quality of life. Studies that observed functional performance from pharmaceutical interventions. The purpose of this study was to conduct a review of the literature and identify studies and patient-reported outcome instruments that purport to measure daytime functioning. METHODS: A search was conducted of the English-language studies published between January 1950 and June 2008 using Medline. Key terms used were ‘daytime function and questionnaires’, ‘daytime functioning and quality of life’, ‘daytime functioning and quality of life’. Studies that observed functional performance from adult population were exclusively selected and of those articles, patient-reported questionnaires were identified. Validity of instruments was assessed based on reported psychometric properties. RESULTS: Total of 55 articles were identified. Studied patient population had sleep disorders (including anxiety (n = 47), cancer (n = 2), restless leg syndrome (n = 2), allergic rhinitis (n = 1), Alzheimer’s disease (n = 1), coronary artery disease (n = 1), overactive bladder (n = 1), and Parkinson’s disease (n = 1). Of these, 45% (n = 25) articles included a patient-reported outcome questionnaire that claimed to measure daytime functioning. The remaining articles (55% n = 30) included objective measurement to describe daytime function or used questionnaires without the supporting evidence of reliability, validity and interpretability. Conclusions: For the purpose of this study, 13 tools identified that changes in patients’ functioning were observed from different areas; generic disease state (i.e. health, social support and activity surveys) (n = 4), sleep disorders (n = 4), fatigue (n = 3), fatigue (n = 3). CONCLUSIONS: Not all studies that purport to measure daytime functioning used validated PRO tools to measure changes in daytime functioning. The criteria of defining daytime functioning were different for different disease states. Future studies that will investigate the domain of daytime functioning, it is recommended to select appropriate validated PRO instruments that can support the intended claim.

FACTORS DRIVING PATIENT SELECTION OF PRIMARY MEDICATION FOR MULTIPLE SCLEROSIS

Jeffrey D., Neurath S., Härle J., Preblick R., By T., Suarez G., Jo H., BMH M1
Wale Forest University School of Medicine, Winston-Salem, NC, USA, 1University of Louisville, Louisv., KY, USA, 2MS Center at HHH, Teaneck, NJ, USA, 3Bayer HealthCare Pharmaceutical, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, USA, 4Bayer Schering Pharma AG, Berlin, Germany

OBJECTIVES: To evaluate the factors driving selection of the primary medication for multiple sclerosis (MS) by patients. METHODS: Baseline data from ROBUST, which is a 12-month, US prospective, observational, open-label, single-arm, multi-center outcomes study of Interferon β-1b given every other day for relapsing forms of MS were analyzed. At baseline, patients were asked to rate the importance of factors that are typically considered before making a decision to select the primary medication to treat MS: (1) How well the medications controls MS progression (Mean [95% Confidence Interval] = 4.72 [4.57–4.86]) followed by their doctor’s recommendation (4.57 [4.41–4.72]); the convenience of taking medication (3.88 [3.63–4.13]), personal research (3.81 [3.56–4.05]) and the convenience of storing the medication (3.71 [3.44–3.98]). These factors and their order of importance remained consistent across patient sociodemographic characteristics, primary medication types and disease severity. CONCLUSIONS: Contributing to the limited published research about factors considered by patients when selecting primary medication for their MS, this analysis found that medication effectiveness to control MS progression and doctor recommendation are the most important drivers of medication selection.

HEALTH-RELATED QUALITY OF LIFE, EDSS AND TIMED 25-FOOT WALK IN A MULTIPLE SCLEROSIS POPULATION OF A REAL-WORLD OBSERVATIONAL OUTCOMES STUDY: BASELINE DATA FROM ROBUST

Jeffrey D., Kirzinger S., Härle J., Preblick R., By T., Gemman EK1
Wale Forest University School of Medicine, Winston-Salem, NC, USA, 1University of Louisville, Louisv., KY, USA, 2MS Center at HHH, Teaneck, NJ, USA, 3Bayer HealthCare Pharmaceutical, Inc., Health Economics, Outcome and Reimbursement (HEOR), Wayne, NJ, USA, 4Quintiles, Inc, Falls Church, VA, USA

OBJECTIVES: To explore the association between baseline health-related quality of life (HRQoL) and clinical measures of disability and motor functioning in a real-world observational study of multiple sclerosis (MS) patients. METHODS: The Real-World Betsaron® Outcomes Study (ROBST) is a prospective, 12-month, observational, single-arm, open-label, multi-center outcomes study of interferon beta-1b given every other day for MS. A total of 226 patients were registered at 52 neurologists’ sites. Clinical measures and patient outcomes were reported by physicians through a web-based data capture tool. The Kurtzke Expanded Disability Status Scale (EDSS) and Timed 25-foot Walk (T25FW; in seconds) were measured by the neurologist at baseline to evaluate patient disability and motor functioning. HRQoL was measured at baseline for 191 patients via the SF-12 Health Survey. For this analysis, EDSS and T25FW were categorized into five (0, 1–2, 2.5–4, 4.5–5.5, 6) and two (< 7, > 7) groups, respectively. SF-12 results were summarized by Physical Component Score (PCS-12) and Mental Component Score (MCS-12). Analysis of variance methods were used to explore the association of FACIT-HRQoL, and clinical measures with EDSS and T25FW. RESULTS: At higher EDSS scores (i.e., worsening disability), both physical and mental HRQoL were lower; however, this association was only statistically significant for PCS-12 (p < .001) for PCS-12, p = .070 for MCS-12. For PCS-12, among EDSS groups, pairwise differences were statistically significant between EDSS 1–2 vs. EDSS 2.5–4, 4.0 (44 vs. 37.2; p = .004), suggesting a marked worsening of physical HRQoL at or above the disability threshold of EDSS 2.5. Both PCS-12 and MCS-12 were higher for the group with better ambulation: T25FW < 7 sec vs. T25FW > 7 sec (43.5 vs. 37.3; p < .001) for PCS-12; 43.9 vs. 41.0, p = .079 for MCS-12. CONCLUSIONS: Physical HRQoL is associated with functional impairment assessed via the EDSS and T25FW. This suggests that the PCS-12 component of the generic HRQoL tool reflects clinical functional impairment in MS patients.

RESPONISIBILITY AND CLINICAL IMPORTANT DIFFERENCES OF THE FUNCTIONAL ASSESSMENT OF MS CLINICAL RESOURCE (FAMS) IN A MULTI-NATIONAL OBSERVATION STUDY

Günther OHL1, Miltenerger C1, Pazzoli C1, Oerlehe R1
1Innovo, Berlin, Germany, 2Innovo, Berlin, Germany, 3University of Rome La Sapienza, Rome, Italy, 4Bayer Schering Pharma AG, Berlin, Germany

OBJECTIVES: Health related quality of life (HRQoL) is an important outcome in multiple sclerosis (MS). As part of the measurement system “Functional Assessment of Chronic Illness Therapy (FACIT)” targeted to the management of chronic illnesses, the Functional Assessment of MS (FAMS) is a self-reported questionnaire assessing patient-reported treatment effects in MS studies. Although the FAMS is validated in MS, the link between meaningful clinical efficacy and FAMS results remains unclear. Objective was to determine anchor-based “clinical important differences” (CID) in FAMS total score (FAMS TS) and FAMS trial outcome index (FAMS TOI) using disability as measured by the Expanded Disability Status Scale (EDSS). METHODS: 6 months data from a prospective, observational study in patients with relapsing MS were used. All patients had been switched from another drug to interferon beta-1b 1–3 months before inclusion. The EDSS, the FAMS-TOIs were assessed at baseline and 6 months, with 1078 respondents at baseline and 950 at follow-up. Regression analysis was used to estimate CID of FAMS change scores by three anchor categories of EDSS change (“deteriorated”, “unchanged”, “improved”). Distribution based measures (standardized effect size (SRM)) were used to quantify the strength of CID. RESULTS: CID of TS at 6 months was 5.63 [95% confidence interval: 3.75 [0.58] (FAMS TS) and 4.22 [0.02, 8.42] (FAMS TOI). Sensitivity coefficients for “EDSS improved” were significantly larger than for “EDSS unchanged” with SRM of 0.24 and 0.23, respectively. CONCLUSIONS: CID estimates are provided for improvement in HRQoL in patients with MS over a six-month period. The results are in line with published CID of health-related outcomes ranging from 4 to 8 units in patients with cancer. The estimated CID can assist clinicians and health policy makers in evaluating significance of short-term treatment effects of medical as well as non-medical interventions (e.g patient support programmes).

COSTS AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GILLES DE LA TOURETTE’S SYNDROME

Bäuerle-Geldsetzer M1, Müller-Vahl K2, Dodel I1, Reese JP1, Oertel WH1, Dodel R1
1i3 Innovus Berlin, Berlin, Germany, 2i3 Innovus, Berlin, Germany, 3University of Rome La Sapienza, Rome, Italy

OBJECTIVES: To assess the costs and the health-related quality of life (HRQoL) of patients with Gilles de la Tourette’s syndrome (GTS) in Germany METHODS: Direct and indirect costs as well as HRQoL were evaluated in 200 patients with GTS in three outpatient departments in Germany. Economic data was provided in a patient diary over a three-months-period. Costs were analyzed from the perspective of the statutory health insurance. Indirect costs were calculated by the human capital approach. HRQoL was measured using the EuroQol instrument. Depression was measured using the Beck Depression Inventory (BDI) and clinical symptoms with the Yale Tourette Syndrome Symptom list (YSSS) and the Shapiro-Tourette-Syndrome-Severity-Scale (STSSS). RESULTS: Direct costs amounted to €635 during the evaluation period. Indirect costs totalled to €230. Patients with GTS had a mean BDI score of 37.5 (range 23–67), which was considerably worse compared to a representative German sample with a mean BDI score of 4.6 ± 5.2. The mean STSSS value was 3.24 ± 1.1. There was no significant difference between genders with respect to tic severity. A significant correlation for BDI, age, YSSS, STSSS, subjective efficacy of